Browse > Article
http://dx.doi.org/10.5125/jkaoms.2016.42.6.365

Prevalence of osteonecrosis of the jaw and oral characteristics of oncologic patients treated with bisphosphonates at the General Hospital of Mexico  

Cuevas-Gonzalez, Maria Veronica (Department of Maxillofacial Prosthetics, General Hospital of Mexico)
Diaz-Aguirre, Celia Minerva (Department of Maxillofacial Prosthetics, General Hospital of Mexico)
Echevarria-y-Perez, Enrique (Department of Maxillofacial Prosthetics, General Hospital of Mexico)
Cuevas-Gonzalez, Juan Carlos (Department of Stomatology, Institute of Biomedical Sciences, Autonomous University of Ciudad Juarez)
Publication Information
Journal of the Korean Association of Oral and Maxillofacial Surgeons / v.42, no.6, 2016 , pp. 365-369 More about this Journal
Abstract
Objectives: To determine the prevalence and oral characteristics of cancer patients treated with bisphosphonates in the oncology and maxillofacial prosthesis departments of the General Hospital of Mexico between 2011 and 2013. Materials and Methods: This cross-sectional study included patients who received prior treatment with bisphosphonates; an intraoral examination was performed by 2 standardized examiners. Results: The prevalence of bisphosphonate-related necrosis in 75 patients was 2.6%; the most common malignancy was breast cancer (84.0%), followed by prostate cancer (16.0%). Exostosis was present in 9.3% of patients and the mean Decayed, Missing, Filled Teeth index was 4.64; 44.0% of the study group had a Community Periodontal Index value between 2 and 2.9 (mean, 0.60). Conclusion: A detailed intraoral assessment must be performed before initiating treatment with bisphosphonates to identify risk factors for osteonecrosis.
Keywords
Prevalence; Osteonecrosis; Bisphosphonates;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. J Oral Maxillofac Surg 2009;67(5 Suppl):2-12.   DOI
2 Fuentes R, Borie E, Sanhueza Campos A, Rebolledo Soto K, Parra Villagran P. Presencia de exostosis orales en pacientes de la ciudad de Temuco, Chile. Avances Odontoestomatol 2012;28:63-9.   DOI
3 de la Fuente-Hernandez J, Gonzalez de Cossio M, Ortega-Maldonado M, Sifuentes-Valenzuela MC. Caries y perdida dental en estudiantes preuniversitarios mexicanos [Dental decay and tooth loss at the high school level in Mexican students]. Salud Publica Mex 2008;50:235-40.
4 Hellstein JW, Marek CL. Bisphosphonate osteochemonecrosis (bisphossy jaw): is this phossy jaw of the 21st century? J Oral Maxillofac Surg 2005;63:682-9.   DOI
5 Filleul O, Crompot E, Saussez S. Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases. J Cancer Res Clin Oncol 2010;136:1117-24.   DOI
6 Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479-91.   DOI
7 Marx RE. Oral & intravenous bisphosphonate-induced osteonecrosis of the jaws: history, etiology, prevention, and treatment. Hanover Park: Quintessence Publishing; 2007:1-65.
8 Correia Vde F, Caldeira CL, Marques MM. Cytotoxicity evaluation of sodium alendronate on cultured human periodontal ligament fibroblasts. Dent Traumatol 2006;22:312-7.   DOI
9 Kim KM, Rhee Y, Kwon YD, Kwon TG, Lee JK, Kim DY. Medication related osteonecrosis of the jaw: 2015 position statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons. J Bone Metab 2015;22:151-65.   DOI
10 Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65:369-76.   DOI
11 Kos M. Incidence and risk predictors for osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. Arch Med Sci 2015;11:319-24.
12 Solomon DH, Mercer E, Woo SB, Avorn J, Schneeweiss S, Treister N. Defining the epidemiology of bisphosphonate-associated osteonecrosis of the jaw: prior work and current challenges. Osteoporos Int 2013;24:237-44.   DOI
13 Casal C, Someso E, Alvarez AM, Farina J, Alvarez T. Osteonecrosis de maxilares relacionada con el uso de bifosfonatos [Osteonecrosis of the jaws related with the use of bisphosphonates]. Farmaceuticos de Atencion Primaria 2012;10:9-14.   DOI
14 Varun B, Sivakumar T, Nair BJ, Joseph AP. Bisphosphonate induced osteonecrosis of jaw in breast cancer patients: a systematic review. J Oral Maxillofac Pathol 2012;16:210-4.   DOI
15 Lee JK, Kim KW, Choi JY, Moon SY, Kim SG, Kim CH, et al. Bisphosphonates-related osteonecrosis of the jaw in Korea: a preliminary report. J Korean Assoc Oral Maxillofac Surg 2013;39:9-13.   DOI
16 Chang JI, Hazboun RC, Chang TI. Incongruities in the AAOMS position paper: medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg 2014;72:2381.
17 Arce C, Bargallo E, Villasenor Y, Gamboa C, Lara F, Perez V, et al. Oncoguia: Cancer de Mama. Mexico City: Instituto Nacional de Cancerologia; 2011:77-86.
18 Robles-Castillo J, Ruvalcaba-Limon E, Maffuz A, Rodriguez-Cuevas S. Breast cancer in Mexican women under 40. Ginecol Obstet Mex 2011;79:482-8.
19 Bonacina R, Mariani U, Villa F, Villa A. Preventive strategies and clinical implications for bisphosphonate-related osteonecrosis of the jaw: a review of 282 patients. J Can Dent Assoc 2011;77:b147.
20 Junquera LM, Martin-Granizo R. Diagnostico, prevencion y tratamiento de la osteonecrosis de los maxilares por bisfosfonatos. Recomendaciones de la Sociedad Española de Cirugia Oral y Maxilofacial (SECOM). Rev Esp Cir Oral y Maxilofac 2008;30:145-56.
21 Khamaisi M, Regev E, Yarom N, Avni B, Leitersdorf E, Raz I, et al. Possible association between diabetes and bisphosphonaterelated jaw osteonecrosis. J Clin Endocrinol Metab 2007;92:1172-5.   DOI